Inhibitor Therapeutics INTI Stock
Inhibitor Therapeutics Price Chart
Inhibitor Therapeutics INTI Financial and Trading Overview
| Inhibitor Therapeutics stock price | 0.08 USD |
| Previous Close | 0.08 USD |
| Open | 0.08 USD |
| Bid | 0.08 USD x 2829900 |
| Ask | 0.08 USD x 2000000 |
| Day's Range | 0.08 - 0.08 USD |
| 52 Week Range | 0.04 - 0.12 USD |
| Volume | 625 USD |
| Avg. Volume | 7.8K USD |
| Market Cap | 13.63M USD |
| Beta (5Y Monthly) | -0.783 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
INTI Valuation Measures
| Enterprise Value | 12.31M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Inhibitor Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.783 |
| 52-Week Change | 61.22% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 0.12 USD |
| 52 Week Low | 0.04 USD |
| 50-Day Moving Average | 0.08 USD |
| 200-Day Moving Average | 0.07 USD |
INTI Share Statistics
| Avg. Volume (3 month) | 7.8K USD |
| Avg. Daily Volume (10-Days) | 810 USD |
| Shares Outstanding | 172.57M |
| Float | 77.56M |
| Short Ratio | 0.08 |
| % Held by Insiders | 57.15% |
| % Held by Institutions | 0% |
| Shares Short | 19.88K |
| Short % of Float | 0.36% |
| Short % of Shares Outstanding | 0.22% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -72.57% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -3353916 USD |
| Diluted EPS (ttm) | -0.02 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.29M USD |
| Total Cash Per Share (mrq) | 0.007 USD |
| Total Debt (mrq) | 58.36K USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.599 |
| Book Value Per Share (mrq) | -0.011 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3030916 USD |
| Levered Free Cash Flow (ttm) | -1832705 USD |
Profile of Inhibitor Therapeutics
| Country | United States |
| State | FL |
| City | Tampa |
| Address | 3014 West Palmira Avenue |
| ZIP | 33629-7264 |
| Phone | 813 864 2562 |
| Website | https://inhibitortx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2 |
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
Q&A For Inhibitor Therapeutics Stock
What is a current INTI stock price?
Inhibitor Therapeutics INTI stock price today per share is 0.08 USD.
How to purchase Inhibitor Therapeutics stock?
You can buy INTI shares on the OTC Markets OTCQB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Inhibitor Therapeutics?
The stock symbol or ticker of Inhibitor Therapeutics is INTI.
Which industry does the Inhibitor Therapeutics company belong to?
The Inhibitor Therapeutics industry is Biotechnology.
How many shares does Inhibitor Therapeutics have in circulation?
The max supply of Inhibitor Therapeutics shares is 172.57M.
What is Inhibitor Therapeutics Price to Earnings Ratio (PE Ratio)?
Inhibitor Therapeutics PE Ratio is now.
What was Inhibitor Therapeutics earnings per share over the trailing 12 months (TTM)?
Inhibitor Therapeutics EPS is -0.02 USD over the trailing 12 months.
Which sector does the Inhibitor Therapeutics company belong to?
The Inhibitor Therapeutics sector is Healthcare.